[go: up one dir, main page]

YU22802A - Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina - Google Patents

Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina

Info

Publication number
YU22802A
YU22802A YU22802A YUP22802A YU22802A YU 22802 A YU22802 A YU 22802A YU 22802 A YU22802 A YU 22802A YU P22802 A YUP22802 A YU P22802A YU 22802 A YU22802 A YU 22802A
Authority
YU
Yugoslavia
Prior art keywords
disorders
isonipectoamides
integrinmediates
treatment
isonipecotamide
Prior art date
Application number
YU22802A
Other languages
English (en)
Inventor
Michael J. Costanzo
William J. Hoekstra
Bruce E. Maryanoff
Original Assignee
Ortho-Mcneil Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical Inc. filed Critical Ortho-Mcneil Pharmaceutical Inc.
Publication of YU22802A publication Critical patent/YU22802A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pronalazak se odnosi na nove deriate izonipekotamida formule (I) koji se mogu upotrebiti za lečenje poremećaja nastalih posredstvom integrina.[The invention is directed to novel isonipecotamide derivatives of Formula (I), which are useful in treating integrin-mediated disorders.
YU22802A 1999-09-29 2000-09-29 Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina YU22802A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15661799P 1999-09-29 1999-09-29
US66713400A 2000-09-21 2000-09-21

Publications (1)

Publication Number Publication Date
YU22802A true YU22802A (sh) 2005-06-10

Family

ID=26853350

Family Applications (1)

Application Number Title Priority Date Filing Date
YU22802A YU22802A (sh) 1999-09-29 2000-09-29 Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina

Country Status (18)

Country Link
US (1) US7718673B2 (sh)
EP (1) EP1133489B9 (sh)
CN (1) CN1352641A (sh)
AR (1) AR034098A1 (sh)
AT (1) ATE300531T1 (sh)
AU (1) AU7711000A (sh)
BR (1) BR0007183A (sh)
CA (1) CA2352957A1 (sh)
CZ (1) CZ20011872A3 (sh)
DE (2) DE60021521D1 (sh)
ES (1) ES2244474T3 (sh)
HU (1) HUP0200439A2 (sh)
NO (1) NO20012612L (sh)
NZ (1) NZ511997A (sh)
PL (1) PL347976A1 (sh)
RU (1) RU2001114518A (sh)
WO (1) WO2001023376A1 (sh)
YU (1) YU22802A (sh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0731088B1 (en) 1990-11-19 2000-10-04 Monsanto Company Retroviral protease inhibitors
US7691843B2 (en) 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
EP2394662B1 (en) 2004-04-02 2018-03-21 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
CA2724435A1 (en) 2008-05-16 2009-11-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
JP2020505333A (ja) * 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2830555A1 (de) 1978-07-12 1980-03-06 Bayer Ag Chinazolinonyl-verbindungen
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
JPH04334357A (ja) * 1991-05-02 1992-11-20 Fujirebio Inc 酵素阻害作用を有するアシル誘導体
WO1993009795A1 (en) 1991-11-22 1993-05-27 Yeda Research And Development Co. Ltd. Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
DE4208051A1 (de) * 1992-03-13 1993-09-16 Bayer Ag Substituierte phenylessigsaeureamide
CA2150550A1 (en) * 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
US6268380B1 (en) 1993-02-19 2001-07-31 G. D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) * 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
AU684547B2 (en) 1993-09-22 1997-12-18 Fujisawa Pharmaceutical Co., Ltd. N-(3-piperidinylcarbonyl)-beta-alanine derivatives as PAF antagonists
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
EP0799202A1 (de) * 1994-12-23 1997-10-08 Dr. Karl Thomae GmbH Piperazinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US5700801A (en) * 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US5602155A (en) * 1995-01-17 1997-02-11 G. D. Searle & Co. Platelet aggregation inhibitors
DE69635417T2 (de) 1995-08-14 2006-07-13 The Scripps Research Institute, La Jolla VERFAHREN UND MITTEL ZUR HEMMUNG DER DURCH ALPHA v BETA 5 VERMITTELTEN ANGIOGENESE
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
CN1085980C (zh) 1995-08-30 2002-06-05 G·D·瑟尔公司 间－胍基、脲基、硫脲基或氮杂环氨基苯甲酸衍生物用作整合素拮抗剂
EP0858457A1 (de) * 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
ES2172780T3 (es) * 1996-03-29 2002-10-01 Searle & Co Derivados de acido fenilpropanoico sustituidos en para como antagonistas de integrina.
SK149798A3 (en) 1996-05-01 1999-10-08 Ortho Mcneil Pharm Inc Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
JP3841898B2 (ja) * 1996-11-21 2006-11-08 三菱電機株式会社 深部線量測定装置
DE69720062D1 (de) 1996-12-09 2003-04-24 Lilly Co Eli Integrin antagonisten
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
EP1124807A1 (en) 1997-10-27 2001-08-22 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6066651A (en) 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
AU1415099A (en) 1997-11-18 1999-06-07 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
AU3213799A (en) 1998-04-01 1999-10-18 Du Pont Pharmaceuticals Company Integrin antagonists
BR9910329A (pt) 1998-05-11 2001-01-30 Novo Nordisk As Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
TW591026B (en) * 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
US6388054B1 (en) 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
WO2000033836A1 (en) 1998-12-04 2000-06-15 Ontogen Corporation 5-membered heterocycles for the treatment of human diseases involving modulators of selectins
JP2003506452A (ja) 1999-08-06 2003-02-18 スミスクライン・ビーチャム・コーポレイション 発作の治療に有用なビトロネクチン受容体アンタゴニスト
BR0013120A (pt) 1999-08-10 2002-04-23 Procter & Gamble Detergente lìquido não-aquoso, com partìculas de enchimento de baixa densidade, solúveis em água de lavagem

Also Published As

Publication number Publication date
WO2001023376A1 (en) 2001-04-05
PL347976A1 (en) 2002-05-06
AR034098A1 (es) 2004-02-04
ES2244474T3 (es) 2005-12-16
EP1133489B9 (en) 2006-05-03
DE60021521T4 (de) 2006-09-21
ATE300531T1 (de) 2005-08-15
EP1133489A1 (en) 2001-09-19
US20030181440A1 (en) 2003-09-25
CA2352957A1 (en) 2001-04-05
BR0007183A (pt) 2002-02-05
DE60021521D1 (de) 2005-09-01
CN1352641A (zh) 2002-06-05
EP1133489B1 (en) 2005-07-27
US7718673B2 (en) 2010-05-18
NO20012612D0 (no) 2001-05-28
HUP0200439A2 (en) 2002-06-29
CZ20011872A3 (cs) 2002-03-13
NO20012612L (no) 2001-07-17
RU2001114518A (ru) 2003-04-20
NZ511997A (en) 2004-12-24
DE60021521T2 (de) 2006-06-08
AU7711000A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
AU1074702A (en) Sulfamides as gamma-secretase inhibitors
MY135841A (en) Novel benzodioxoles
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
DK1200418T3 (da) Nematodicide trifluorbutener
BG106585A (en) Kinase inhibitors as therapeutic agents
PL366590A1 (en) Novel compounds as anti-inflammatorz, immunomodulatory and anti-proliferatory agents
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
MXPA03012013A (es) Derivados de 1-oxa-2,8-diaza-spiro[4,5]dec-2-eno sustituidos como medicamento para el tratamiento de dolor.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
MY141011A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
MY117381A (en) Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis
IS6914A (is) 2-þíó-útskiptar imídasólafleiður og notkun þeirraí lyfjaiðnaðinum
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
PL365165A1 (en) Tricyclic imidazopyridines
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
MXPA04003544A (es) Benzotriazepinas como ligandos del receptor de gastrina y colecistocinina.
MXPA03010205A (es) Derivados de acido oxalico.
BR0012921A (pt) Compostos calcilìticos
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
MY136138A (en) Hexacyclic compounds
MXPA04001048A (es) Imidazopiridinas sustituidas con alquilo, para el tratamiento de trastornos gastrointestinales.